Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
By L. Beaugerie, N. Brousse, A. Bouvier, J. Colombel, M. Lémann, J. Cosnes, X. Hébuterne, A. Cortot, Y. Bouhnik, J. Gendre and 5 more. The Lancet, 2009
993 citations recorded by the source corpus.
Subfields: Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/7400098d4b774633a249e840154270bb29f8e756
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Guidelines for the management of inflammatory bowel disease in adults (2011, background): “More recently, a large prospective study followed almost 20 000 consecutive patients over a 3-year period for the incidence of lymphoproliferative disorders. Those patients receiving maintenance thiopurines had a fivefold increased risk compared to those who had previously or never received the drug”
- The burden of inflammatory bowel disease in Europe. (2013, background): “117 However, the French study may have been influenced by selection bias and a recent unselected nationwide Danish cohort study of 45,986 patients with inflammatoryboweldisease (1997 – 2008) reported a more modestly increased risk of lymphoid tissue cancer in IBD patients using thiopurines (RR,…”